GW Pharmaceuticals PLC- ADR (Nasdaq:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today noted that the American Academy of Neurology (AAN) issued a press release today on GW’s investigational medicine, Epidiolex® (pure cannabidiol, or CBD).
Data in the AAN release are from physician-led FDA authorized Epidiolex “expanded access” programs for children and young adults with treatment-resistant epilepsy that have exhausted available treatment options. The data provide treatment effect information on a total of 137 patients who have at least 12 weeks of Epidiolex exposure. Safety data is provided on 213 patients, representing these 137 patients plus additional patients still in their first 12 weeks of treatment.
Additional data will be presented in a poster at the AAN Annual Meeting on 22 April at 6.15pm EDT, at which time GW will make an additional disclosure.
“We are pleased that the American Academy of Neurology has chosen to highlight the importance of the Epidiolex expanded access data and look forward to more detailed information at the forthcoming AAN Annual Meeting being made available by the physicians leading this program,” stated Justin Gover, GW’s Chief Executive Officer.
FDA authorized expanded access programs facilitate access to investigational drugs for treatment use in patients with serious or immediately life-threatening diseases or conditions, who lack therapeutic alternatives. Patients in the Epidiolex expanded access program included those with Dravet syndrome and Lennox-Gastaut syndrome (LGS), epilepsy types that can lead to intellectual disability and lifelong seizures, as well as 10 other types of severe epilepsy. Many have extreme and rare forms of epilepsy including several patients with major congenital structural brain abnormalities.
In parallel with the expanded access program, GW is advancing its formal clinical development program in order to seek FDA approval for Epidiolex in the treatment of Dravet syndrome and Lennox-Gastaut syndrome, two rare and catastrophic forms of epilepsy. GW recently commenced the first of two Phase 3 trials in Dravet syndrome and expects to commence Phase 3 trials in LGS in the second quarter of 2015. (Original Source)
Shares of GW Pharmaceuticals closed today at $96.41, up $5.09 or 5.57%. GWPH has a 1-year high of $111.46 and a 1-year low of $41.86. The stock’s 50-day moving average is $88.24 and it’s 200-day moving average is $77.94.
On the ratings front, GW Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on April 8, Piper Jaffray analyst Joshua Schimmer reiterated a Buy rating on GWPH, with a price target of $147, which implies an upside of 60.3% from current levels. Separately, on January 8, Cowen’s Phil Nadeau reiterated a Buy rating on the stock and has a price target of $110.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joshua Schimmer and Phil Nadeau have a total average return of 16.0% and 30.9% respectively. Schimmer has a success rate of 68.6% and is ranked #212 out of 3574 analysts, while Nadeau has a success rate of 71.1% and is ranked #128.
GW Pharmaceuticals PLC is engaged in the research, development and commercialisation of cannabinoid prescription medicines to meet patient needs.